Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

theoptionsplug Apr. 14 at 5:22 AM

THINGS TO WATCH, TUESDAY, 4/14/26 👁️ $CAR $JPM $JNJ $C $WFC

0 · Reply

Jimsonlima Apr. 14 at 3:34 AM

$JNJ forgot earnings was coming. i missed my chance to short

0 · Reply

DonCorleone77 Apr. 14 at 1:03 AM

$JPM $JNJ $WFC $C $BLK Some notable companies reporting before tomorrow's open, with earnings consensus estimates:** - JPMorgan (JPM), consensus $5.51 - Johnson & Johnson (JNJ), consensus $2.68 - Wells Fargo (WFC), consensus $1.60 - Citi (C), consensus $2.63 - Blackrock (BLK), consensus $11.48 - Albertsons (ACI), consensus 44c

0 · Reply

Sandals_Spreads Apr. 13 at 9:33 PM

$JNJ Johnson & Johnson reports tomorrow. Defensive name in a week where the macro backdrop is anything but defensive. Strait still closed. Blockade active. SPX sitting on a historic setup. Full context here: https://open.substack.com/pub/sandalsandspreads/p/rare-spx-signal-suez-hormuz-2026?utm_source=share&utm_medium=android&r=7do8ew

0 · Reply

Bazzzigar Apr. 13 at 9:16 PM

$JNJ $270+

0 · Reply

The__short_squeezer Apr. 13 at 8:58 PM

$WMT $ORCL $MU $SNDK $JNJ There was a lot of pessimism at the beginning of the day, but the market ended with gains for both SPY and NDX. Trump proved that the naval blockade he imposed on Iran was the right thing to do, and the smart money showed that it supported his decision because this naval blockade will force Iran to surrender to him if it does not want to collapse economically.

0 · Reply

Suite510 Apr. 13 at 8:43 PM

$JNJ $ABT baby issues 🤣🤣🤣🤣🤣

0 · Reply

DragonAlgo Apr. 13 at 7:39 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $237.50 | Type: CALL Option Plan (premium): Entry: $4.22 Stop: $3.04 TP1: $5.49 TP2: $7.18 TP3: $10.14 Volatility regime is active. 🔗 https://dragonalgo.com

0 · Reply

PoochDaddyTrader Apr. 13 at 7:34 PM

$JNJ $250 tomorrow!

0 · Reply

eWhispers Apr. 13 at 7:09 PM

#earnings after the close on Monday, April 13, 2026, and before the open on Tuesday, April 14, 2026 https://www.earningswhispers.com/calendar $JPM $BLK $C $KMX $JNJ

0 · Reply

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

JPM DIA TRV

Apr 12, 2026, 2:00 PM EDT - 1 day ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Apr 10, 2026, 8:00 AM EDT - 3 days ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 9, 2026, 7:57 AM EDT - 4 days ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 8, 2026, 10:41 AM EDT - 5 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 7, 2026, 8:00 AM EDT - 6 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Mar 30, 2026, 9:14 AM EDT - 14 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 28, 2026, 10:00 AM EDT - 16 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 17 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 17 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 19, 2026, 1:00 PM EDT - 25 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 25 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 26 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 26 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 26 days ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 26 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 4 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 4 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 5 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 5 weeks ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 5 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 8:03 AM EST - 5 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 6 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 26, 2026, 2:30 PM EST - 6 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 6 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 7 weeks ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 7 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 7 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 7 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:00 PM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 7 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 7 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 18, 2026, 10:44 AM EST - 7 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 7 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 7 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 7 weeks ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 13, 2026, 4:19 PM EST - 2 months ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 2 months ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 2 months ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 2 months ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 2 months ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 2 months ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 2 months ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 2 months ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 2 months ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 2 months ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 2 months ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 2 months ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

theoptionsplug Apr. 14 at 5:22 AM

THINGS TO WATCH, TUESDAY, 4/14/26 👁️ $CAR $JPM $JNJ $C $WFC

0 · Reply

Jimsonlima Apr. 14 at 3:34 AM

$JNJ forgot earnings was coming. i missed my chance to short

0 · Reply

DonCorleone77 Apr. 14 at 1:03 AM

0 · Reply

Sandals_Spreads Apr. 13 at 9:33 PM

0 · Reply

Bazzzigar Apr. 13 at 9:16 PM

$JNJ $270+

0 · Reply

The__short_squeezer Apr. 13 at 8:58 PM

0 · Reply

Suite510 Apr. 13 at 8:43 PM

$JNJ $ABT baby issues 🤣🤣🤣🤣🤣

0 · Reply

DragonAlgo Apr. 13 at 7:39 PM

0 · Reply

PoochDaddyTrader Apr. 13 at 7:34 PM

$JNJ $250 tomorrow!

0 · Reply

eWhispers Apr. 13 at 7:09 PM

#earnings after the close on Monday, April 13, 2026, and before the open on Tuesday, April 14, 2026 https://www.earningswhispers.com/calendar $JPM $BLK $C $KMX $JNJ

0 · Reply

humblegambler Apr. 13 at 6:10 PM

$MSOS $YCBD $LLY $JNJ $MRK "This is the inflection point. CMS has established a structured, physician-supervised framework for hemp-derived cannabinoids within Medicare, and the bar to participate credibly is high requiring clinical data, institutional-grade documentation and healthcare supply infrastructure. cbdMD has spent years preparing for such framework." "We recognize physicians and health systems evaluating this category will not accept consumer-grade marketing claims or products without published safety data. They require OECD-standard toxicology, human clinical data, drug interaction transparency, and documentation that can withstand institutional review. That evidence base does not exist broadly in this category, cbdMD has built it” https://www.prnewswire.com/news-releases/cbdmd-launches-clinical-healthcare-channel-to-support-first-federal-pathway-for-hemp-derived-cbd-in-medicare-302730460.html

1 · Reply

Skimman Apr. 13 at 5:47 PM

$JNJ Earnings in the morning

0 · Reply

SuperGreenToday Apr. 13 at 5:41 PM

$JNJ Share Price: $235.91 Contract Selected: May 08, 2026 $235 Calls Buy Zone: $5.48 – $6.77 Target Zone: $10.11 – $12.36 Potential Upside: 74% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/

1 · Reply

profit_guru Apr. 13 at 5:33 PM

$ABBV - $JNJ releases earnings tomorrow if they have strong quarter it will rally whole biotech

0 · Reply

hyenacorp Apr. 13 at 5:27 PM

$JNJ

1 · Reply

PoochDaddyTrader Apr. 13 at 5:12 PM

$JNJ lets go

0 · Reply

flordi Apr. 13 at 4:32 PM

$JNJ 530

0 · Reply

1986iamwallstreet Apr. 13 at 3:48 PM

if $JNJ want to go in defensive mode and compete in the metabolic disease area they could buy $MDGL

0 · Reply

TeresaTrades Apr. 13 at 1:31 PM

This week's Earnings Calendar $JPM $TSM $ASML $JNJ $BAC

0 · Reply

Quantumup Apr. 13 at 12:42 PM

Guggenheim reiterated Top Pick $SYRE Buy; $115 after Spyre announced topline results for SPY001's monotherapy study in SKYLINE-UC Part A (n~130). $TAK $JNJ ABBV ABVX APGE Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2043670136456954126?s=20

0 · Reply

Bazzzigar Apr. 13 at 11:36 AM

$JNJ in

0 · Reply

The__short_squeezer Apr. 13 at 11:24 AM

$WMT $ORCL $MU $SNDK $JNJ

2 · Reply

Market Cap	574.36B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.34
Forward PE	20.91
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	7,663,500
Avg Vol	8,331,798
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	31%
Beta	0.34
Analysts	Strong Sell
Price Target	$243.76